09-18-2017 11:43 AM CET - Health & Medicine

Future Trends and Outlook of Global Cancer Biomarkers Market CAGR of 12.2% and USD 27.4 Billion by 2024

Press release from: Data Bridge Market Research
The “Global Cancer Biomarkers Market”, By Tumor (Breast, Lung, Prostate), By Type (Protein Biomarker, Genetic Biomarkers), By Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), By Application (Diagnostic, Drug Discovery, Prognostic), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Industry Trends and Forecast to 2024

The Global Cancer Biomarkers Market has accounted to USD 10.9 billion in 2016, growing at a CAGR of 12.2% from 2017 to 2024, and is expected to reach USD 27.4 billion by 2024.

• No of pages : 350
• No of Figures: 60
• No of Tables: 220

Ask for Sample Report Visit @ databridgemarketresearch.com/request-a-sample/?dbmr=globa...

Cancer biomarkers are the molecules secreted by a tumor or a specific response of the human body indicating the presence of cancer. The biomarkers enable cancer detection at an early stage and facilitate high-speed noninvasive diagnosis using various genomics and proteomics tools. Cancer biomarkers are used for various applications such as cancer diagnostics, drug discovery and development, prognostics, personalized medicine, and surrogate endpoints. Over the years, cancer biomarkers have become an integral part of research in pharmaceutical and clinical trial companies, as they help to reduce the time and cost of the drug discovery and development process.

Global Cancer Biomarkers Market – Competitive Landscape

The major players in the Global Cancer Biomarkers Market are turning to strategies such as mergers, acquisition and new product developments as major market strategies to penetrate the market.

Some of the major players operating in this market are:

• Abbott Laboratories
• DiagnoCure Inc.
• Affymetrix, Inc.
• Illumina, Inc.
• Qiagen N.V.
• Roche Diagnostics Ltd.
• Agilent Technologies Inc.
• Quest Diagnostics Inc.
• Merck & Co. Inc.
• Hologic, Inc.
• Becton Dickinson and Company among others.

Speak to Analyst about Global Cancer Biomarkers Market Visit @ databridgemarketresearch.com/speak-to-analyst/?dbmr=globa...

Global Cancer Biomarkers Market – Market Segmentation

In this report, the cancer biomarkers market is segmented on the basis of type, cancer type, profiling technology, application, and geography.

Based on type, the Cancer Biomarkers Market is broadly split into three segments, namely, protein biomarkers, genetic biomarkers, and other biomarkers (includes viral, cell, and carbohydrate biomarkers).

Based on cancer type, the Cancer Biomarkers Market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other cancers (includes melanoma, leukemia, gastric, kidney, liver, and pancreatic cancers).
The cancer biomarkers market, by profiling technology, is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics. The omics technologies segment accounted for the largest share of the global cancer biomarkers market in 2015. The largest share of this segment is mainly attributed to the increased adoption of advanced high throughput technologies in biomarker discovery and development and increasing use of omics-based tests for cancer diagnosis and drug development process.

Read more about the Global Cancer Biomarkers Market Report Visit @ databridgemarketresearch.com/reports/global-cancer-biomar...

Global Cancer Biomarkers Market – Geographical Segmentation

Based on geography the Global Cancer Biomarkers Market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others. In 2016, North America is expected to dominate the market with a share of 34.7%, growing at a CAGR of 11.2% in the forecast period 2016 to 2022. The dominance of North America is owing to high incidence of cancers such as breast and lungs, coupled with favorable reimbursement scenarios and highest treatment success rate.

Related Report

Global Radiopharmaceuticals Market – Industry Trends and Forecast to 2024
Global Radiopharmaceuticals Market, By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)– Industry Trends andForecast To 2024

Report Access: databridgemarketresearch.com/reports/global-radiopharmace...

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Investor: investors@databridgemarketresearch.com
Visit Blog: databridgemarketresearch.com/blog/
Follow us on LinkedIn: www.linkedin.com/company/data-bridge-market-research

This release was published on openPR.
News-ID: 722605 • Views: 210
More releasesMore releases

You can edit or delete your press release here: